cas 60-00-4, EDTA | Articles data

Articles about 60-00-4Total 24 be found

Article title
Article abstract
Author
Journal number and time
Download

-
-
Anderson,Gaunt
p. 190
(1960)
Read Online

MAKING ETHYLENEDIAMINETETRAACETIC ACID
Provided is a method of making ethylenediaminetetraacetic acid (EDTA) comprising the steps: (a) providing a reaction mixture (a) comprising ethylenediamine (EDA) and glycolonitrile (GN), wherein reaction mixture (a) comprises 0% to 0.1% by weight, based on the weight of reaction mixture (a), of any base having pKa of the conjugate acid (PKaH) of 13 or higher; (b) causing or allowing reaction mixture (a) to react to form a dinitrile (DN) compound; (c) bringing the DN into contact with aqueous solution of a base having pKaH of 11 or higher, and causing or allowing the resulting mixture to react to form a diacid compound (DA); (d) causing or allowing the DA to react, either sequentially or simultaneously, with additional GN to form products (Pd); (e) causing or allowing products (Pd) to react with a base having pKaH of 11 or higher, to form EDTA. Also provided is a composition comprising a diacid/dinitrile compound (DADN) wherein each -R has the structure:
-
Paragraph 0047-0064

(2020/12/30)

A high and constant hydration of the nuclear magnetic resonance imaging contrast agent and its preparation method
The invention relates to a nuclear magnetic resonance imaging contrast agent with a high hydration constant and a preparation method of the nuclear magnetic resonance imaging contrast agent. The nuclear magnetic resonance imaging contrast agent with the high hydration constant is a gadolinium (III) complex containing nitrogen oxygen groups. The nuclear magnetic resonance imaging contrast agent prepared by the gadolinium (III) complex has the advantages of high hydration constant, relatively good stability and high relaxation rate.
-
Paragraph 0065

(2018/03/01)

Ethylenediamin four process for the production of acetic acid
The invention relates to a production technology of ethylenediamine tetraacetic acid (EDTA). Iminodiacetonitrile or a derivative thereof and dihaloethane are used as raw materials to prepare EDTA, and a finished product of EDTA is prepared by the steps of substituted addition, hydrolysis, active carbon decoloration, acidification and centrifugal drying, wherein the reaction yield is very high and can exceed 95%, and the content is greater than 99%. According to the production technology provided by the invention, without using a virulent raw material, the safety performance is greatly improved; meanwhile, by replacing ethylenediamine with cheap dihaloethane, the cost is greatly reduced, and the economic and social benefits are very good.
-
Paragraph 0040-0042

(2017/01/23)

Synthesis and Characterization of CeO2 Nanoparticles via Solution Combustion Method for Photocatalytic and Antibacterial Activity Studies
CeO2 nanoparticles have been proven to be competent photocatalysts for environmental applications because of their strong redox ability, nontoxicity, long-term stability, and low cost. We have synthesized CeO2 nanoparticles via solution combustion method using ceric ammonium nitrate as an oxidizer and ethylenediaminetetraacetic acid (EDTA) as fuel at 450°C. These nanoparticles exhibit good photocatalytic degradation and antibacterial activity. The obtained product was characterized by various techniques. X-ray diffraction data confirms a cerianite structure: a cubic phase CeO2 having crystallite size of 35 nm. The infrared spectrum shows a strong band below 700 cm-1 due to the Ce-O-Ce stretching vibrations. The UV/Vis spectrum shows maximum absorption at 302 nm. The photoluminescence spectrum shows characteristic peaks of CeO2 nanoparticles. Scanning electron microscopy (SEM) images clearly show the presence of a porous network with a lot of voids. From transmission electron microscopy (TEM) images, it is clear that the particles are almost spherical, and the average size of the nanoparticles is found to be 42 nm. CeO2 nanoparticles exhibit photocatalytic activity against trypan blue at pH 10 in UV light, and the reaction follows pseudo first-order kinetics. Finally, CeO2 nanoparticles also reduce CrVI to CrIII and show antibacterial activity against Pseudomonas aeruginosa.
Ravishankar, Thammadihalli Nanjundaiah,Ramakrishnappa, Thippeswamy,Nagaraju, Ganganagappa,Rajanaika, Hanumanaika
p. 146 - 154
(2015/04/27)

Extraction buffer and method for isolating high-quality RNA from cells exposed to metal chloride solutions and clay mineral suspensions
An RNA extraction buffer, an RNA extraction method, and an RNA extraction kit are described which enable functional, rapid, efficient, and high-quality RNA isolation from samples containing high concentrations of aqueous metal cations, clays, silica, or silicate minerals.
-
(2015/12/17)

USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE
Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that for Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I) wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a group C═Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; R2, R3 and R6 represent hydrogen; R4 and R5, independently of each other, represent hydrogen, lower alkyi or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable derivatives thereof; or wherein R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyi, halo-lower alkyi, hydroxy-lower alkyi, lower alkoxy-lower alkyi, acyloxy-lower alkyi, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents oxygen; R′ represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; R2, R3 and R6 represent hydrogen; R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable derivatives thereof. Methods of treatment of neoplastic and autoimmune diseases with these compounds are also disclosed.
-
(2014/04/03)

CHELATING AGENT PRECURSORS, FLUIDS CONTAINING THEM, AND THEIR USE
The present invention relates to a chelating agent precursor that contains glutamic acid N,N-diacetic acid (GLDA) and/or methylglycine N,N-diacetic acid (MGDA) wherein at least one of the carboxylic acid groups is presentas a carboxylic acid derivative selected from the group of amides, anhydrides, and esters, combinations thereof, and salts thereof, provided that it is not the triethyl ester of GLDA, the triethyl mono-t-butyl ester of GLDA, the tri-t-butyl ester of GLDA, the monobenzyl tri-t-butyl ester of GLDA, any ester or amide that contains azacycloalkane groups, any amide that contains biotin groups, any amide that contains minoethylcarbamoyl based amide groups, (S)-diethyl 2,2'-(1-benzyloxy)-1,5-dioxo-5-(prop-2-ynylamino)pentan-2-ylazanediyl-diacetate, diethyl 2,2'-(5-(3-azidopropylamino)-1-(benzyloxy)-1,5-dioxo-pentan-2-ylazanediyl-diacetate, the trimethyl ester of MGDA, the monomethyl ester dimethylamide of MGDA, the dibenzyl ester of MGDA, the dibenzyl mono t-butyl ester of MGDA, the di t-butyl ester of MGDA, the di-t-butyl- monobenzyl ester of MGDA, N,N-bis(benzyloxycarbonylmethyl)-N'-methoxycarbonylmethyl-alanine amide, or N,N- bis(tert-butoxycarbonyl)-N'-methoxycarbonylmethyl-alanine amide, and esters of GLDA immobilized on a gel, and that the amide is not the amide of ammonia, to a fluid containing the above chelating precursor and a liquid, and to the use of a chelating agent precursor of MGDA and GLDA and fluids containing them in an application wherein delayed acidity or chelating capacity is useful, such as in descaling, bleaching, cleaning, and treating oil and/or gas-containing subterranean formations.
-
Page/Page column 20

(2012/09/11)

Homogeneous humanized antibodies against JAM-A that inhibit proliferation
The present invention relates to humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the invention relates to anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The invention also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The invention also relates to a method for the preparation of such humanized antibodies.
-
(2012/06/01)

PROCESS FOR PRODUCTION OF ETHYNYLTHYMIDINE COMPOUND USING 5-METHYLURIDINE AS STARTING RAW MATERIAL
The present invention provides a process for producing 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, which is useful as a medicine, in an efficient and industrially advantageous manner, and more specifically, provides a process for producing 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine as shown below. (wherein R1 and R2 independently represent a protective group for a hydroxy group, or R1 and R2 together form a protective group for two hydroxy groups, R3 and R4 independently represent a protective group for a hydroxy group, R5 represents a protective group for a hydroxy group, R6 represents a protective group for a hydroxy group, X represents a leaving group, and Y represents a halogen atom.)
-
Page/Page column 58

(2011/02/19)

Lightening Agents and/or Dyes that Contain Aldehyde(s)
Agents for dyeing and/or lightening keratin fibers, in particular human hair, containing, relative to the weight thereof, 0.001 to 15 wt. % of at least one aldehyde of the formula (I): wherein X represents —CH(R2)—SO2—Y—R1, —CR3R4R5, or wherein Y represents —CH(CHO)— or —CH2— or a chemical bond, and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 independently represents —H or —CN or —F or —Cl or —Br or —I or —CHO or —NH2 or —NO2 or —CF3 or —CCl3 or —CF2CF3 or —CCl2CCl3 or an optionally substituted (C1-C6) alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C1-C6) alkylene group, and wherein the agent contains no oxidation dye precursors of developer and coupler type.
-
(2010/12/29)

Imaging of Enzyme Activity
This invention relates to biochemistry and magnetic resonance imaging.
-
(2008/06/13)

Methods and compositions for synthesis of 3'-aminolinkers
Methods and compositions for 3′-aminomodifier CPG and 3′-aminomodified oligonucleotides are disclosed. Microarrays or biochips with 3′-aminomodified oligonucleotides are disclosed. A variety of detectable labels can be attached to 3′-aminomodified oligonucleotides.
-
(2008/06/13)

Imaging thrombus with glycoprotein llb/llla antagonists
This invention relates to a method of using a radiolabeled small molecule antagonist of the platelet IIb/IIIa receptor for the diagnosis of arterial and venous thrombi.
-
(2008/06/13)

Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
The invention relates to transport molecule binding ligand compounds which comprise a therapeutically and/or diagnostically active substance and a carrier molecule-affine substance with a high association constant to the carrier molecule. The invention also relates to medicaments containing these ligand compounds and to diagnostic kits.
-
(2008/06/13)

Preventing and/or treating cardiovascular disease and/or associated heart failure
Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
-
(2008/06/13)

Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
-
(2008/06/13)

Methods for detection of nucleic acid sequences in urine
Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of diseases, such as cancer and pathogen infections, and detection of genetic predisposition to various diseases. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs. The invention also encompasses methods for evaluating the effects of environmental factors and aging on the genome.
-
(2008/06/13)

Sex determination in cattle, sheep and goats using y-chromosome polynucleotides
A nucleic acid isolate capable of hybridizing only to y-chromosome specific DNA sequences of cattle, sheep goats and other ruminants. A method for determining the sex chromosome constitution of a tissue or cell sample using the nucleic acid isolate is also disclosed.
-
(2008/06/13)

Determination of genetic sex in ruminants using Y-chromosome specific polynucleotides
Nucleic acid isolates capable of hybridizing only to the Y-chromosome specific DNA sequences of cattle, sheep and goats are described, as are methods for the determination of the sex chromosome constitution of a tissue or cell sample.
-
(2008/06/13)

Iron chelate solutions
A method for the preparation of an aqueous solution of iron polyprotic acid chelate complexes, comprising reacting a solution of a mixture of a first polyprotic acid or a salt thereof, said first acid being capable of chelating iron, and a second polyprotic acid or a salt thereof, said second acid being capable of chelating iron and being different from the first acid, with iron in the presence of an oxidizing agent, with the proviso that at least part of the carboxylic acid groups in the first and second acids is present in salt form and at least part of the carboxylic acid groups in the first and second acids is present in acid form. Preferably, the first and second polyprotic acids may be selected from ethylenediaminetetraacetic acid (EDTA), N-hydroxyethyl-ethylenediaminetriacetic acid (HEDTA), and diethylenetriaminepentaacetic acid (DTPA), and the iron is selected from Fe-powder, Fe(OH)2 and FeCO3. Part of the polyprotic acid groups in the first and second acids is present in the salt form, the salt being selected from ammonium and alkali metal ions, in particular K , Na and mixtures thereof. The method makes it possible to obtain aqueous solutions containing high contents of iron, such as up to approximately 7% by weight of iron, for use as a plant nutrient, mainly in soil-free plant culturing.
-
(2008/06/13)

Adhesive components containing alkanediyl-bis-carboxamides for the treatment of collagen
In the application of an adhesive component to a collagen-containing material such as tooth or a bone, the improvement wherein the adhesive component comprises a compound of the formula STR1 in which R1 denotes hydrogen or methyl, R2 and R4 denote divalent aliphatic radicals having one to three carbon atoms, R3 denotes hydrogen or formyl (--CO--H), X denotes hydrogen or (meth)acryloyl STR2 and n represents 0 or 1, with the proviso that if R3 equals H, n is zero. Those compounds are new in which R3 denotes formyl and n represents 1.
-
(2008/06/13)

Stabilized aqueous folic acid preparation
This invention relates to a stabilized aqueous folic acid preparation which comprises a folic acid component selected from the group consisting of folic acid, ammonium, alkali metal and alkaline earth metal salts of folic acid and mixtures thereof, and which has an improved stability of its folic acid contents in the presence of oxygen, the said preparation containing as a stabilizer a combination of (a) at least one member selected from the group consisting of dihydrofolic acid and ammonium, alkali metal, alkaline earth metal and alkanolammonium salts thereof, and (b) at least one member selected from the group consisting of at least one hydroxypolycarboxylic acid and ammonium, alkali metal, alkaline earth metal and alkanolammonium salts thereof.
-
(2008/06/13)

Manganese (II) chelate manufacture
The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20° to 50° C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA. The Mn(II) chelate precipitates and low osmolarity solutions formed by the above processes are also aspects of this invention.
-
(2008/06/13)

Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
Disclosed herein are nasal spray compositions and methods for enhancing polypeptide absorption across nasal membranes comprising a chelating agent and a polypeptide in a pharmaceutically acceptable excipient.
-
(2008/06/13)